FDA Will Solicit sNDAs For Well-Researched Off-Label Uses, Gottlieb Says
The agency’s move is a reaction to the potentially decreased importance of registration due to adequate off-label reimbursement.
The agency’s move is a reaction to the potentially decreased importance of registration due to adequate off-label reimbursement.